1) cracked team with strong industry experience + connections (easily the top 1-2 in all of desci imo), 2) structural advantage in accuracy, cost and speed in early stage discovery that scales in tandem with advancements in frontier, open-source model releases (boltz-2, boltzgen), 3) insane blueskies scenario (token would like 5x overnight lol), but still a very good base case as well, 4) actually doing real science (i say this as a desci lover)

Geopolitical conservatism in biotech risks becoming anti-progress. Biosecurity matters but scientific talent is globally distributed and the tools for discovery should be too. @metanova_labs mission is more important than ever. Decentralized, permissionless infrastructure isn't just an ideological position — it's a practical response to a growing problem that ultimately affects all of us. Immigration to the global centers where institutions, capital, and infrastructure are concentrated is harder than ever. At the same time, access to frontier AI is increasingly determined by jurisdiction. As evidenced by @AnthropicAI recent restrictions on Fable and others, the tools that enable scientific discovery are becoming concentrated within a relatively small number of (or single) countries. This has implications for who can contribute to scientific innovation and from where. Roughly 2/3 of Nobel science laureates were not born in the United States, and approximately 40% of U.S. Nobel science prizes awarded since 2000 went to immigrants. Meanwhile, proposals such as a $100k H-1B fee, travel restrictions affecting dozens of countries, and compute export controls under the BIS AI Diffusion Framework are making participation in frontier research increasingly unequal. If similar restrictions had existed throughout the last century, many of the discoveries, companies, and medicines we rely on today may never have emerged. #Bittensor# offers a market-driven alternative for coordinating talent, capital, compute, and scientific innovation across borders.

We’ve assembled a lineup of individual Subnet Keynotes from some of the most exciting teams building on Bittensor. Each keynote will spotlight a different part of the subnet economy: @micaelabazo, @metanova_labs — decentralised AI for pharma and drug discovery. @0xcarro, @TargonCompute — confidential compute infrastructure through TEEs. @tm0klc, @manakoai — vision models and Manako, turning Bittensor-powered computer vision into enterprise use cases. @mast3rdubs, @hippius_subnet — decentralised storage and cloud infrastructure. @kenjon, @bitmind — deepfake detection and AI content verification. @shardiban, @oroagents — the open arena for AI agents. June 2-3, Bittensor Track at Proof of Talk.

New NOVA Blueprint update We are making our chemical search competition significantly more exploration-focused. Starting Wed May 20, 2026 00:00 UTC, submissions containing molecules that are too chemically similar to each other will be rejected entirely. Why this matters: In real drug discovery campaigns, the most valuable search strategies are not the ones that generate many near-identical molecules around the same idea. The real challenge is finding multiple distinct scaffolds that perform well. Once you discover a promising scaffold, generating variations around it is relatively easy. What is hard — and far more valuable — is exploring chemical space broadly enough to uncover entirely new starting points. That is why we originally introduced entropy thresholds in Blueprint, and this new update pushes that philosophy further. We are explicitly rewarding algorithms that: - explore broadly - surface diverse chemical ideas - avoid collapsing into narrow clusters of near-duplicates The goal is not just higher scores but rather better chemical navigation strategies for real-world discovery. This update should lead to: * more novel molecular starting points * stronger search algorithms * and ultimately better drug discovery systems #Bittensor# #SN68# #DrugDiscovery# #AI# #DeSci#

Long-term corticosteroid use is associated to many serious health conditions like osteoporosis, cataracts and glaucoma, besides wreaking havoc on metabolism. For many autoimmune disorder patients though, it's the price they have to pay for controlling inflammation. IL-6 works as a major inflammation amplifier in the body and targeting it can lead to more precise therapeutics that can help these patients avoid corticosteroid use altogether.

New NOVA nanobody target is live: IL-6 (Interleukin-6) IL-6 is one of the central signaling proteins behind inflammation and immune regulation. When dysregulated, it has been implicated in: - autoimmune disorders - chronic inflammation - neuroinflammation - blood-brain barrier disruption Making it a highly relevant target for inflammatory, neurological, and immune-related diseases. The IL-6 inhibitor market is already worth billions annually, with drugs targeting this pathway generating multi-billion dollar revenues across autoimmune and inflammatory indications, validating both the biological and commercial importance of the target. Miners across NOVA will now compete to design nanobodies targeting IL-6 in an open, adversarial discovery environment. Top submissions may also be selected for wet lab validation through our partnership with @Yalotein, helping close the loop between decentralized virtual screening and real-world biologics development. #Bittensor# #SN68# #DrugDiscovery# #Biotech# #Nanobodies# #DeSci#